The Guidelines Caught Up. The Denial Letter Did Not.

Between 2024 and 2026, four professional bodies did something that quietly changes how an injury case involving orthobiologics gets argued. They wrote the standard down.

ESSKA and the International Cartilage Regeneration and Joint Preservation Society published a formal consensus on platelet-rich plasma for knee osteoarthritis. The American Academy of Orthopaedic Surgeons published a technology overview built on a systematic review. The American Academy of Physical Medicine and Rehabilitation issued a guidance statement in 2026. The American Society of Interventional Pain Physicians published a 119-page practice guideline on regenerative therapies for chronic low back pain, with 19 recommendations, every one at 100% agreement among the consensus panel.

None of that is advertising. It is a paper trail. A claim is made of paper trails.

What now exists, and how each document was built

The method matters more than the conclusion, because the method is what a defense expert has to attack.

• ESSKA-ICRS consensus, 2024. Built with the RAND/UCLA Appropriateness Method — 216 defined clinical scenarios rated by a panel, crossing age, grade of arthritis, compartment, effusion, and what had already been tried.
• ESSKA-ORBIT consensus, 2024. Twenty-eight question-and-statement sets on blood-derived products, each carrying a letter grade from A (high-level scientific support) down to D (expert opinion), then rated for agreement by a separate panel.
• AAOS Technology Overview, 2024. A systematic review that came back with 54 articles, 36 of them high quality, on PRP for knee osteoarthritis against every common comparator including saline, corticosteroid, hyaluronic acid, exercise, and bone marrow concentrate.
• AAPM&R guidance statement, 2026. A technical expert panel and a modified Delphi process, built on a structured literature review updated through June 2025, producing five evidence-based recommendations and eleven consensus-based best practices.
• ASIPP guidelines, 2025 update. Thirty-five authors, GRADE methodology, indication-by-indication evidence levels for the lumbar spine.
• Multispecialty chronic pain guidelines, 2024. Sixteen questions appraised against United States Preventive Services Task Force criteria, spanning tendinopathy, muscle, joint, disc, and neuropathic indications.

Professional societies do not convene panels, run Delphi rounds and publish appropriateness tables about treatments they consider unsettled curiosities. They do it when a treatment is in wide clinical use and the profession needs to say where it belongs and where it does not.

What the documents say about joints

The ESSKA-ORBIT panel issued three grade A statements — its highest evidentiary tier. There is sufficient preclinical and clinical evidence to support PRP use in knee osteoarthritis. Clinical evidence shows effectiveness in mild to moderate disease, Kellgren-Lawrence grade 3 or below. And PRP provides a longer effect than the short-lived effect of corticosteroid injection, with a safer profile — the statement that drew the strongest agreement of the entire document.

The ESSKA-ICRS panel went finer. Of its 216 scenarios, 38.9% were rated appropriate, 4.2% inappropriate, and 56.9% uncertain. The strongest consensus was for PRP after injective treatments had already failed. Appropriate, in that document, means a patient aged 80 or under, with grade 0 to 3 arthritis, who has already been through conservative care.

Underneath the consensus statements sit meta-analyses of randomized trials. Compared with hyaluronic acid across 18 level-1 studies, PRP produced a 44.7% mean improvement in total WOMAC score against 12.6% — and leukocyte-poor preparations outperformed leukocyte-rich ones. A 2024 network meta-analysis found PRP, bone marrow concentrate and hyaluronic acid all outperforming corticosteroid on pain and function at a minimum of six months. A 2025 meta-analysis found the improvement clinically significant, and dependent on how much platelet concentration was actually delivered.

What the documents say about the injured spine

ASIPP graded each lumbar indication separately, and the grades are not interchangeable:

• Intradiscal PRP — Evidence Level III, Fair. Consensus recommendation: Moderate.
• Intradiscal bone marrow aspirate concentrate — Level III, Fair. Moderate.
• Epidural PRP — Level III, Fair. Moderate.
• Facet joint PRP and mesenchymal stem cells — Level IV, Limited. Moderate.
• Sacroiliac joint PRP — Level IV, Limited. Low.

That is not a marketing table. It is a society telling its own members exactly how far the evidence reaches for each target, and where it thins out. The same guideline says regenerative medicine “remains in early stages of clinical validation” and asks for careful optimism. Both halves are true at once, and the honest version of this page carries both.

The sentence in these documents that nobody quotes

Every one of them sequences the treatment. ASIPP stipulates that regenerative therapy follows a thorough diagnostic evaluation and runs alongside structured exercise, physical therapy and lifestyle management. The ESSKA-ICRS appropriateness ratings are built on what has already been tried and failed. PRP as a first move, before anything has been diagnosed or attempted, is the one thing the knee consensus explicitly declines to endorse.

That is a rule about order, and it is the rule most often broken — by clinics that sell an injection as a product, and by claims that arrive with a biologic line item and no diagnostic work in front of it. An injection is not the treatment. It is what makes the treatment possible.

Where the record is thin, because the other side will find it

It is indication-specific, and so is every honest sentence about it.

ASIPP's own table is the clearest example: intradiscal PRP and bone marrow concentrate at Level III, Fair; epidural PRP at Level III, Fair; facet joint injection at Level IV, Limited; sacroiliac at Level IV, Limited. Four targets a few inches apart, and four different evidentiary tiers. A citation earned at one target does not travel to the next one, and a defense expert who knows that table will say so.

The 2019 ESSKA meniscus consensus is equally direct: it does not establish biological enhancement as a treatment that improves the healing of a repaired meniscus. That is a society declining to endorse an indication, and a claim that asserts otherwise is exposed.

And the reporting itself is uneven. A systematic review of 25 randomized trials in knee osteoarthritis found they reported, on average, 53.1% of the items on the orthopedic profession's own minimum reporting checklist. Not one hit 80%. The category reported worst was activation — a variable that changes what the injectate actually is.

None of that makes the knee and elbow evidence disappear. It means a treatment described only as “PRP” on a bill has not really been described at all. Why the characterization is the treatment.

Why a consensus statement matters to your claim

Two things get argued about medical care in an injury case: whether it was necessary, and whether its value was reasonable. Both are argued from the standard of care as the literature describes it.

Before these documents, an adjuster could treat a biologic injection as an outlier and value it accordingly. After them, a treatment given for a documented indication that maps onto a published scenario is not an outlier — it is care delivered inside a written standard, and the person disputing it has to argue with the society that wrote it, under oath, in front of someone whose job is to notice. What Daubert asks of that argument.

Coverage is a separate question with a separate answer. Most plans do not pay for these injections, and that is a budgeting decision about what a plan funds across its whole membership — not a finding about whether the treatment works. The difference between not covered and not proven.

How this is actually practiced here

The guidelines describe a sequence. So does the clinic.

Diagnosis comes first, and it is a real diagnosis: imaging read against the examination, electrodiagnostic testing where the question is nerve, and diagnostic blocks where the question is which structure carries the signal. A block that abolishes the pain and lets it return on schedule has proven something. A block that does nothing has disproved something cheaply, before anyone injected anything expensive into it. How a diagnostic block earns its place.

Then the terrain. These products are autologous — the injectate is made from the patient, so the patient’s biology is the raw material. Systemic inflammation, insulin resistance, poor sleep and nicotine are not lifestyle footnotes here; they are the manufacturing conditions. Why we measure the terrain before we inject.

Then delivery, under ultrasound or fluoroscopic guidance, with the preparation characterized and recorded. Then function measured at intervals, in numbers, so that improvement is a data series and not a memory. And alongside all of it, the unglamorous work — loading the tissue, sleeping, eating in a way that lowers the inflammatory background. Roughly half of what happens in this practice is behavioral, and it is the half that decides whether the other half holds.

What to ask before you agree to any biologic injection

1. What is the diagnosis, and what test established it?
2. Which published guideline or consensus scenario does my situation map onto, and where does it fall in that document?
3. What is being injected — platelet dose, leukocyte content, volume, whether it is activated?
4. Under what imaging is it being placed?
5. What measure will tell us at three months whether it worked, and what happens if it did not?
6. What is being done about the biology that will be there tomorrow?

A clinic that can answer those six is practicing inside a standard. A clinic that cannot is selling a syringe, and the record it produces will not survive contact with a defense expert.

Frequently asked questions

Is PRP still considered an unsettled treatment?

Not by the bodies that write the standards. Between 2024 and 2026, ESSKA and ICRS, the AAOS, AAPM&R and ASIPP all published consensus documents or guidance with graded recommendations, and those grades are indication-specific rather than blanket. Coverage is a separate matter from evidence. Learn more: Not covered is a budget decision, not a verdict on the evidence.

What does Level III, Fair, with a moderate recommendation actually mean?

It is ASIPP’s grading for intradiscal and epidural PRP in chronic low back pain: the supporting studies are mostly observational or lower-tier controlled evidence, appraised with GRADE, and the panel reached moderate consensus that the treatment has a role in appropriately selected patients. It is a measured statement, not a promise. Learn more: What a pain society actually says about injecting an injured disc.

Does a guideline make my treatment automatically defensible in a claim?

No. It makes the argument a medical one instead of a rhetorical one. What carries a claim is the record: a diagnosis established by a test, an indication that maps to a published scenario, the product characterized, the guidance modality named, and function measured over time. Learn more: Write the note like a defense expert will read it.

Is PRP appropriate for every painful joint after a crash?

No, and the honest reading of the evidence is that it is indication-specific. The knee and lateral elbow evidence is comparatively strong; randomized-trial meta-analyses in Achilles tendinopathy and rotator cuff disorders did not show clinical benefit. A citation earned in one joint does not transfer to another. Learn more: What the knee guidelines say, grade by grade.

Why does the clinic test metabolic markers before injecting?

Because the injectate is made from you. Platelet products act on the tissue environment they land in, and a persistently inflamed, insulin-resistant environment is working against the repair you are paying for. Learn more: Why the terrain comes before the biologic.

Will my health plan pay for this?

Usually not. Most commercial plans and Medicare do not cover orthobiologic injections, and the ASIPP guideline instructs clinicians to tell patients so before treatment. Non-coverage is a decision about what a plan funds, and prior authorization for anything is not a guarantee of payment. Learn more: How coverage and evidence get confused.

Where is Injury Experts located?

Injury Experts is at 4477 Woodson Rd, Suite 202, St. Louis, MO 63134, next to Lambert International Airport, serving the St. Louis region in Missouri and Illinois. Call (314) 887-5866 or text (314) 886-5902.

Key takeaways

• Four societies published graded guidance on orthobiologics between 2024 and 2026; the grades are indication-specific and do not transfer between joints.
• Every one of those documents sequences the treatment: diagnosis first, conservative care first, biologic after — and alongside exercise, rehabilitation and lifestyle management.
• The evidence is negative in some indications, including Achilles tendinopathy and rotator cuff disorders, and that belongs in an honest account.
• Most plans do not pay for these injections. Non-coverage is a budgeting decision, not a finding about whether the treatment works.
• In a claim, what carries the treatment is the record: indication mapped to a published scenario, product characterized, placement guided, function measured.

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP — Board Certified in Anesthesiology, Pain Medicine, Interventional Pain Management, Addiction Medicine, and Obesity Medicine.

This article is for general education and is not medical advice. It does not create a physician–patient relationship. Do not start, stop, or change any medication — including opioid medication — without consulting your physician.